Enliven Therapeutics
ELVN
45 hedge funds and large institutions have $735M invested in Enliven Therapeutics in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 6 reducing their positions, and 8 closing their positions.
164,020% more call options, than puts
Call options by funds: $8.21M | Put options by funds: $5K
886% more capital invested
Capital invested by funds: $74.5M → $735M (+$660M)
600% more funds holding in top 10
Funds holding in top 10: 1 → 7 (+6)
494.71% more ownership
Funds ownership: 17.36% → 512.07% (+495%)
233% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 6
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
25% more funds holding
Funds holding: 36 → 45 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$161M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
+$118M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$63.9M |
| 4 |
VA
VR Adviser
New York
|
+$45M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$42.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$11M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$3.54M |
| 3 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$703K |
| 4 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$154K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$142K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GVAG
51
Great Valley Advisor Group
Wilmington,
Delaware
| – | -$55.9K | -3,415 | Closed |
|
52
Charles Schwab
San Francisco,
California
| – | -$47.1K | -2,880 | Closed |
|
|
FWA
53
Freedom Wealth Alliance
Brookfield,
Wisconsin
| – | -$12.7K | -775 | Closed |
|
ELVN Hedge Fund Activity: Q1 2023 in Review
45 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q1 2023, worth a combined $735M — up 886% from $74.5M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ELVN positions and 8 closed out — a net gain of 9 holders — while 20 added to existing stakes and 6 trimmed.
The largest buyer was OrbiMed, adding an estimated $161M. The largest seller was BML Capital Management, cutting an estimated $11M.
- 45 institutional investors held Enliven Therapeutics (ELVN) as of Q1 2023, up from 36 in Q4 2022.
- Funds reported $735M of Enliven Therapeutics stock for Q1 2023, up 886% quarter-over-quarter.
- 17 funds opened new Enliven Therapeutics positions in Q1 2023 and 8 closed out, a net change of +9 holders.
- The largest Enliven Therapeutics buyer in Q1 2023 was OrbiMed, an estimated $161M added.
- The largest Enliven Therapeutics seller in Q1 2023 was BML Capital Management, an estimated $11M sold.
Based on aggregated 13F filings for Q1 2023.